ArticleInternational journal of clinical pharmacy2013
Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
Article in International journal of clinical pharmacy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Pooled it
- Pharmacist-led deprescribing interventions for cancer patients in a specialist palliative care setting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol.Journal of geriatric oncology · 2024Article
- Polypharmacy, chemotherapy receipt, and medication-related out-of-pocket costs at end of life among commercially insured adults with advanced cancer.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2022Article
- Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.Journal of cancer research and clinical oncology · 2020Article
- Missed opportunities: unnecessary medicine use in patients with lung cancer at the end of life - an international cohort study.British journal of clinical pharmacology · 2018Article
- Impact of medication review, within a shared decision-making framework, on deprescribing in people living in care homes.European journal of hospital pharmacy : science and practice · 2017Article
- Polypharmacy and potentially inappropriate medication use in geriatric oncology.Journal of geriatric oncology · 2016Review
- Supportive Care in Older Adults with Cancer: Across the Continuum.Current oncology reports · 2016Review
- Symptom burden in lung cancer: management updates.Lung cancer management · 2016Review
- 'I don't think I'd be frightened if the statins went': a phenomenological qualitative study exploring medicines use in palliative care patients, carers and healthcare professionals.BMC palliative care · 2016Article
- Recommendations to support deprescribing medications late in life.International journal of clinical pharmacy · 2015Article
- The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Article
- Prevalence and factors associated with polypharmacy in older people with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Inappropriate prescribing in patients accessing specialist palliative day care services.International journal of clinical pharmacy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolypharmacy-taking five or medications per day-is common in lung cancer patients. This patient group is prescribed medication to control acute symptoms associated with cancer and also to prevent or treat other long-term conditions. These medications increase the pill burden for the patient and also the probability of developing a drug-related toxicity.
objectiveTo assess the prevalence of inappropriate medication in patients taking erlotinib for the treatment of advanced non-small cell lung cancer.
methodThis was a multicentre study across three sites in the North of England. Medication histories for patients receiving erlotinib were retrospectively extracted from medical notes and assessed by the clinical team (a consultant pharmacist, nurse specialist and clinical oncologist) to determine if the medication was appropriate or inappropriate. The clinical team considered the following factors when deciding if the medication was appropriate or inappropriate: remaining life expectancy of the patient, time until benefit of the treatment, goals of care and treatment targets.
resultsAmong the 20 patients assessed, 19 (95 %) according to the clinical team were taking medications that were inappropriate. The mean number of medications the patients were taking was 8 (range 1-16) and the most common class of medication used were drugs affecting the Central Nervous System. In addition, there were 11 patients (55 %) who were taking erlotinib in combination with a proton pump inhibitor (PPI)-a clinically significant drug interaction that impairs the absorption of erlotinib.
conclusionsPatients taking erlotinib for the treatment of advanced non-small cell lung cancer take many inappropriate medications for the treatment or prevention of long-term conditions. These patients should have their medications reviewed in the context of their original therapeutic goals.
Indexed as
Identifiers
23229875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.